# Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

> **NCT04231864** · PHASE2 · WITHDRAWN · sponsor: **Alain Algazi**

## Conditions studied

- Epstein-Barr Virus Positive
- Metastatic Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma
- Stage IVA Nasopharyngeal Carcinoma
- Stage IVB Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Epacadostat

## Key facts

- **NCT ID:** NCT04231864
- **Lead sponsor:** Alain Algazi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Feasibility
- **Last updated:** 2020-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231864, "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04231864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*